← Back to Clinical Trials
Recruiting NCT06177717

Deep Functional Phenotyping of the ALA Lung Health Cohort

Trial Parameters

Condition Lung Diseases
Sponsor Johns Hopkins University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,000
Sex ALL
Min Age 25 Years
Max Age 35 Years
Start Date 2024-02-12
Completion 2026-07-30

Brief Summary

The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with: * the structure of the participants lungs' airways, * the structure of blood vessels in the participants lungs and heart, and * the participants lungs' ability to exchange gases. Participants will take four different lung function tests to measure lung function, including: * air movement in the lungs (oscillometry) * lung size (slow vital capacity (SVC) and functional residual capacity (FRC) * gas transfer in the lungs (diffusing capacity for carbon monoxide (DLCO).

Eligibility Criteria

Inclusion Criteria: * Age 25-35 years at the time of the baseline examination * Able to read and understand English or Spanish * Has a social security number * Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination. Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation. * Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant Exclusion Criteria: 1. Severe asthma, which is defined as any of the following: * Current (i.e. at the time of the visit) Global Initiative for Asthma (GINA) Step 4 or higher therapy (medium dose inhaled corticosteroid/long-acting beta agonist (ICS/LABA) or high dose inhaled corticosteroid \[ICS\] or add-on long-acting muscarinic antagonist (LAMA); Medium dose = \>250 fluticasone,

Related Trials